KKCG
Technology

KKCG
technology

Our business is built on our inherent strengths – KKCG's size and resources, ability to succeed in new markets, expertise in the IT and biotechnology sectors, and experience with effective management.

Show success stories

1/1 our success

ARICOMA Group continues expansion into international markets

3
key acquisitions
9 companies
in the ARICOMA Group

960 mil. CZK
EBITDA value

Accelerated digital transformation and entry into new international markets are the components of the long-term strategy of the largest ICT holding company in the Czech Republic, the ARICOMA Group. At the end of last year, the group started an acquisition campaign, which continues this year. The company’s portfolio, which includes companies such as AUTOCONT, Cleverlance, AEC and Dataspring, ARICOMA Group, has now expanded with three major technological players – Seavus, Komix and Stratiteq.

Technology

The future development of the IT pillar of KKCG’s business to rely on the ARICOMA technology holding

With a portfolio comprising leading Czech and foreign companies, ARICOMA's strategy is based on the trend that more and more businesses are changing the ways in which they use IT services. The goal is to provide new-generation IT services that guarantee comprehensive coverage for customers' diverse needs. Our flagship, AUTOCONT, specializes in ICT corporate infrastructure and enterprise information systems. We develop software and provide IT outsourcing, ICT security, and cloud services, and our portfolio includes contact centers. We have state-of-the-art data centers in Prague and South Moravia that offer not only secure storage, but also maximum data exploitability. The reliability of our data centers is guaranteed by Tier III certification.

We help startups launch growth and global expansion

We rely on partnerships with global technology leaders and the extensive expertise of our professionals. Our vision is to create permanent value based on strong and lasting partnerships with the entrepreneurs we support, and with other investors. We are a partner to small and large enterprises in helping them streamline IT operations, reduce operating costs, and improve flexibility to facilitate the implementation of development plans.

We invest in expensive biotechnology

Biotechnology research and the transfer of the results derived from it to the marketplace is a very costly, high-risk enterprise. KKCG is one of a small number of Czech corporations engaged in this area. We develop state-of-the-art medical devices that improve the quality of life for patients. Our funding provides support for clinical trials of Senescence and MitoTam developed by Professor Jiří Neužil at the Institute of Biotechnology.